

Accepted Manuscript

Title: Old Friends with New Faces: are Sodium Channel Blockers the Future of Adjunct Pain Medication Management?


Author: Ashley M. Thomas, Timothy J. Atkinson

PII: S1526-5900(17)30681-8

DOI: <http://dx.doi.org/doi: 10.1016/j.jpain.2017.08.001>

Reference: YJPAI 3453

To appear in: *The Journal of Pain*



Please cite this article as: Ashley M. Thomas, Timothy J. Atkinson, Old Friends with New Faces: are Sodium Channel Blockers the Future of Adjunct Pain Medication Management?, *The Journal of Pain* (2017), <http://dx.doi.org/doi: 10.1016/j.jpain.2017.08.001>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Old Friends with New Faces: Are Sodium Channel Blockers the Future of Adjunct Pain Medication Management?

Author details:

Ashley M. Thomas, Pharm.D, BCPS; Clinical Pharmacy Specialist;
VA Tennessee Valley Healthcare System; Murfreesboro, TN USA

Timothy J. Atkinson, PharmD, BCPS, CPE; Clinical Pharmacy Specialist, Pain Management
Director, PGY-2 Pain & Palliative Care Pharmacy Residency Program
VA Tennessee Valley Healthcare System; Murfreesboro, TN USA

Corresponding author:

Dr. Ashley Thomas
3400 Lebanon Pike
VA Tennessee Valley Healthcare System
Murfreesboro, TN 37129
Email: awaddell@samford.edu

Disclosures:

This project was not funded.
Dr. Thomas: Nothing to disclose
Dr. Atkinson: Consultant, Axial Healthcare Inc.

Highlights

- **Specific subtypes of voltage gated sodium channels (Nav1.1-1.9) linked to inflammatory and nociceptive pain.**
- **Pharmacokinetic studies reveal misconceived drug interactions with oxcarbazepine**
- **Carbamazepine and oxcarbazepine may be currently underutilized for certain pain syndromes.**
- **There is a call for additional research for carboxamide subclass of sodium channel blockers in pain**

Abstract:

Providers are being asked to decrease the emphasis and overutilization of long-term opioid therapy, but many are left without proper guidance on appropriate utilization of non-opioid therapies. Furthermore, therapeutic options are quite limited and many providers lack confidence in distinguishing available alternatives. Once patients have failed 1st line therapy, there is an apparent lack of knowledge on how to proceed with choosing subsequent therapy. To choose amongst alternative agents, an understanding of pharmacology, pharmacokinetics, and efficacy in targeting various pain conditions is necessary. This article focuses on the use of the carboxamide class of sodium channel blockers (carbamazepine, oxcarbazepine, eslicarbazepine) for adjunct pain medication management including research updates in pharmacology, pharmacokinetics, and current evidence for pain along with promising areas of research. It is an evidence update for clinical use of sodium channel blockers, clarifies misconceptions regarding their use, and highlights emerging research for improved pain targets that justifies additional study. We performed a complete review of the literature using the search terms *oxcarbazepine*, *carbamazepine*, and *eslicarbazepine* in conjunction with *pharmacokinetics*, *adverse effects*, *pharmacology*, *voltage-gated sodium channel subtype*, *neuropathic pain*, *inflammatory pain*, *metabolism*, *epoxide metabolite formation*, *drug interactions*, *CYP450 interactions*, *pain phenotype*, and *chronic pain management*. Databases searched included PubMed and Google Scholar. Package inserts were utilized for drug structure illustration, adverse reactions, and bioavailability. Pharmacology and pharmacokinetic data were taken from randomized controlled trials evaluating this area as well as in vitro published results. For validity, only peer-reviewed literature was included. Evidence for sodium channel blockers in chronic pain management was limited. This review focuses on highlighting the data available for the use of sodium channel blockers for certain pain syndromes as well as underutilized potential. Emerging

literature on sodium channel subtypes and their connection to neuropathic, inflammatory and mechanical pain transmission is elucidated. The authors also scrutinize literature surrounding the pharmacokinetics of oxcarbazepine and eslicarbazepine to provide clearer guidance to the significance of any drug interactions and refute assumptions made based on structural similarity to carbamazepine and its known undesirable drug interactions. Side effect profiles are outlined and compared, emphasizing the differences between agents. Sodium channel blocker doses used in certain pain syndromes are outlined with a call for further research to better understand their place in chronic pain management. Identification of sodium channel subtypes with links to specific pain conditions and the ability to target them hints at the potential for truly individualized therapy. Sodium channel inhibitors are underutilized based on available evidence, and emerging research has identified this area as promising for additional clinical trials to better guide clinical practice.

Perspective: This article provides a review of the pharmacology, evidence for pain and pharmacokinetics of oxcarbazepine, carbamazepine and eslicarbazepine. There is a disparity in evidence using sodium channel blockers for pain and this article highlights the potential that is currently underutilized. The authors believe this will catalyze interest for further studies.

Keywords: Oxcarbazepine, carbamazepine, eslicarbazepine, sodium channel blockers, adjunct therapy, chronic pain management

Introduction:

Chronic pain affects more than 100 million people in the United States every year, with 30-40 million reporting moderate to severe pain daily.³⁸ The lack of appropriate treatment and optimal care is multifactorial, however, poor understanding of appropriate therapies, namely non-opioid pain medications plays a significant role.⁴⁵ Providers are being asked to decrease the use of long-term opioid therapy, but many are left without proper guidance on appropriate utilization of non-opioid therapies.⁶² Furthermore, therapeutic options are quite limited and many providers lack confidence in distinguishing available alternatives.⁴⁶ It is imperative that chronic pain be addressed and managed with therapy specific to the pain syndrome. While opioids may be indicated for some patients, it is difficult to achieve pain control and decrease reliance on opioid therapy without a thorough understanding of how to choose non-opioid therapies. It is essential, therefore, to understand the benefits and risks of each therapeutic alternative and adjunct agent to both combat the current opioid epidemic and sufficiently manage chronic pain.

Targeted approaches are being encouraged to treat pain syndromes based on the etiology.³⁸ In addition to examining pain pathology, providers are being asked to characterize pain based on nociceptive, neuropathic, inflammatory, somatic or visceral symptomatology.²⁶ Once distinguished, targeted medication management is key. Many are generally familiar with 1st line therapies for inflammatory and neuropathic pain. However, once patients have failed 1st line therapy, many providers have expressed that they lack the expertise to effectively differentiate or utilize subsequent therapeutic treatment options.

One class of medications that may currently be underutilized as an alternative for pain is voltage-gated sodium channel blockers, specifically the carboxamide subclass, which includes carbamazepine (Tegretol®), oxcarbazepine (Trileptal®), and recently eslicarbazepine (Aptiom®). This may be due to limited experience and data compared to first-line therapies. However, to appropriately manage pain, providers must become more familiar with second and third line medications and develop an understanding of where each class of

medications fits into therapy. In order to choose amongst alternative agents, an understanding of pharmacology, pharmacokinetics, and efficacy in targeting various pain conditions is necessary. This article is an update of evidence for clinical use of sodium channel blockers, clarifies misconceptions regarding their use, and highlights emerging research for improved pain targets that justifies additional study.

Pharmacologic Targets:

Na channels:

Voltage-gated sodium channels have been identified as contributing to pain syndromes through enhanced electrical currents and increased sodium channel density at sites of injury, both mechanisms leading to hyper excitability and increased pain transmission.^{17,34,35} There are nine identified voltage-gated sodium channel subtypes (Nav1.1-1.9) and multiple Navs have been linked to transmission of inflammatory, nociceptive, and neuropathic pain.^{5,15,17,35,37,48,55,67,69} Furthermore, specific Navs have been identified recently with correlations to specific types of pain indicating that targeting overactive channels may be an oversimplification of the complex biological process involved in pain signaling.^{37,67,69} Please see Figure 1 for Navs linked to pain and associated pain syndromes.

<Figure 1>

Nav1.9 is found majorly distributed in the peripheral nervous system while Nav1.8 is mostly distributed in the C-fibers of the dorsal root ganglia; however, there is evidence to support channel presence of Nav1.7, Nav1.8, and Nav1.9 in dorsal root ganglia neurons with preferential small-diameter neurons, most of which are nociceptors.^{15,18,55} Thereby highlighting their involvement in pain transmission. Sodium channel subtypes are categorized as tetrodotoxin-resistant (TTX-R) or tetrodotoxin-sensitive (TTX-S). Nav1.8 and Nav1.9 are known to be TTX-R.⁵⁵ TTX-R currents have been shown to be largely involved in current transmission in nociceptive

neurons, which is dynamically adjusted by response to injury.^{55,67} Increased TTX-R channel activity was found in inflammation linked dorsal root ganglia neurons.⁵⁵ Inflammatory mediators have also been shown to up-regulate Nav1.8 and Nav1.7 and were linked to increased expression and enhanced current induction of Nav1.9, suggesting involvement in the maintenance of inflammatory response.^{5,55,67,69} Moreover, Nav1.8 protein levels were shown to be elevated in dorsal root ganglia neurons surrounding inflamed limbs.⁶⁷ Studies allude to a link between Nav1.7 in mechanical and inflammatory pain, Nav1.8 to visceral pain and Nav1.9 to inflammatory pain transmission.^{67,69} There have also been reports that suggest Nav1.8 involvement in neuropathic pain.^{53, 67,69}

Voltage-gated sodium channel alterations and expression in specific disease states and pain syndromes is also noteworthy. It is hypothesized that dysregulation of beta₂- subunit of sodium channels is involved in the development of allodynia.⁶⁷ Nav1.3 has been reported to be detectable only in injured nerves and found to be up regulated in dorsal root ganglia neurons by nerve injury.^{67,69,17} Up regulation of Nav1.3, Nav1.6, Nav1.7, and Nav1.9 are observed in diabetic neuropathic pain.⁶⁷ Nav1.3 has been shown to be upregulated at the site of peripheral nerve damage as well as upregulated in nociceptive dorsal horn neurons following experimental spinal cord injury¹⁷; it is believed that Nav1.3 may be involved in neuropathic pain after nerve and spinal cord injury.⁶⁹ Nav1.2 is mainly expressed on non-myelinated axons and has been linked to multiple sclerosis(MS).⁶⁷

Voltage-gated sodium channel mutations are also associated with multiple pain syndromes.^{17,18,21,22} A well-recognized mutation in Nav1.7 is present in human erythromelalgia.^{17,18} Mutations in Nav1.7, Nav1.8 and Nav1.9 have been strongly linked specifically to neuropathic pain.^{5,16,21,22,35,37,69} Nav1.8 is expressed within Perkinje neurons in MS and deviations in SCN10A have been shown to predict the degree of cerebellar dysfunction in MS.³⁵ Lastly, there is data to support that in patients with paroxysmal extreme pain disorder (PEPD), Nav 1.7, although activated by normal stimuli, does not deactivate appropriately, which leads to persistent sodium currents.^{67,69}

Targeting of specific pain conditions through an associated sodium channel subtype is intriguing and has the potential to transform our current understanding and routine management of pain. Researchers are not entirely certain that pharmacologic agents can be successfully designed to selectively inhibit individual Navs. However, there is research in the pipeline for a drug that selectively targets Nav1.7 as well as one that selectively targets Nav1.8.^{10,35,39} Recently, use of a drug designed to target Nav1.7 (BIIB074) was evaluated in patients with trigeminal neuralgia in a withdrawal phase2a trial.⁷² The sample size was small and the results were not statistically significant, but nearly twice as many failures occurred in the placebo group compared to (BIIB074). The results were promising and highlight the importance of further investigation.⁷²

Additional research into which specific receptor subtypes are associated with each of the current pharmacologic agents is warranted and may guide focused research into specific pain types where data does not currently exist to guide therapy.

Pharmacology:

Sodium channels undergo structural changes in response to depolarization; the channel phases through active (open), inactive, and resting or repriming states.¹⁷ Agents must selectively inhibit voltage-gated sodium channels that are upregulated into an overactive state. Studies refer to overactive channels as the inactive state rather than the resting state of sodium channels.⁶³

Current sodium channel blockers in the pharmacologic carboxamide subclass all bind to the alpha subunit of voltage-gated sodium channels. All three selectively inhibit sodium channels in the inactive state, carbamazepine and oxcarbazepine with an affinity greater than ten times that of the channel in resting formation, and eslicarbazepine with an affinity three times greater than that of carbamazepine.^{1,2,11,52}

Carbamazepine, oxcarbazepine, and eslicarbazepine have similar chemical structures. Oxcarbazepine was designed to avoid the 10,11-epoxide metabolite of carbamazepine to which are attributed many of its serious side effects^{23,41} Eslicarbazepine is the (s)-isomer of the monohydroxy derivative (MHD), which is the active metabolite of oxcarbazepine most responsible for its activity.³² Carbamazepine, oxcarbazepine and eslicarbazepine have not demonstrated specificity toward any particular Nav based on current literature.

<Table 1 >

Pharmacokinetics:

Carbamazepine and oxcarbazepine have nearly identical chemical structures, so it's understandable that many have assumed similar pharmacokinetic and adverse effect profiles. Understanding the differences, however, is crucial to appropriate use assessment. Oxcarbazepine differs from carbamazepine by one critical substitution to intentionally avoid the epoxide metabolite of carbamazepine and improve its overall tolerability. As a result, oxcarbazepine is metabolized very differently than carbamazepine. Carbamazepine utilizes the CYP450 enzyme system as a primary pathway of metabolism, leading to multiple drug interactions, including inducing its own metabolism.⁶¹ Because of their structural similarities, it was presumed that oxcarbazepine would display a similar pharmacokinetic profile. However, in contrast to carbamazepine, oxcarbazepine has only minor interaction with the CYP450 enzyme system.^{23,28,59}

Oxcarbazepine has historically been considered a prominent CYP3A4 inducer, similar to carbamazepine. Pharmacokinetic studies have shown a lack of enzyme induction as well as autoinduction.^{44,50} Additionally, pharmacodynamic studies specifically evaluating the effect of oxcarbazepine on two known CYP substrates, erythromycin and cimetidine, each showed no change in serum concentrations of erythromycin or cimetidine when compared to monotherapy.²⁸ Conversely, other pharmacodynamics studies have raised questions about

potential CYP3A4 induction properties. Oxcarbazepine was shown to reduce the area under the curve (AUC) of felodipine by ~28% as well as enhance the metabolism of quinidine.^{4,70} Many providers accepted the conclusion that oxcarbazepine was an inducer of CYP450 enzymes until one investigator proposed that induction properties may be dose dependent. The results of this evaluation validated that oxcarbazepine does not possess CYP3A4 induction properties until doses of 900mg per day or greater are used, and even at higher doses it is considered a weak inducer.⁵³ It is not entirely clear if the MHD metabolite is responsible for the induction properties; however, as oxcarbazepine is found almost entirely metabolized to MHD, it's most likely the true inducer. Eslicarbazepine reportedly showed no induction properties in vitro on human hepatocytes, but observed reduction in serum levels of simvastatin and birth control, lead to questions regarding the true pharmacodynamic profile.^{8,24} Eslicarbazepine doses of 800mg per day or greater were used in each study evaluating the CYP3A4 induction properties potentially indicating a similar dose-dependent phenomenon as oxcarbazepine, but this has not yet been sufficiently confirmed in available studies.⁸

The MHD metabolite of oxcarbazepine was shown to inhibit CYP2C19 at normal concentrations and CYP2C9 at concentrations that exceed normal dosing of oxcarbazepine.²⁸ Similarly, eslicarbazepine has been shown to inhibit CYP2C19.⁸ Few drugs utilize CYP2C19 for metabolism; therefore this inhibition has not translated to clinical significance. Eslicarbazepine, the s-isomer of MHD, predictably demonstrates almost identical metabolism as oxcarbazepine.⁷¹

Pharmacodynamic studies evaluating the use of oxcarbazepine and eslicarbazepine in combination with warfarin have also been completed. Oxcarbazepine, even at doses of 900mg per day or greater, did not clinically impact INR.^{28,43} Eslicarbazepine at doses of 1,200mg per day was shown to reach the level of statistical significance, but minimally impact serum levels of S-warfarin and there was no clinically significant effect on INR.^{8,66} Oxcarbazepine and eslicarbazepine have both been shown to decrease serum levels of birth control at

higher doses.^{4,8,24,52} This may be due to induction of CYP3A4, but it is also hypothesized that this interaction may stem from either inhibited absorption or potentially accelerated metabolic clearance.

Pharmacodynamic studies have clearly shown that oxcarbazepine does not share the risk of clinically significant drug interactions that are well characterized with carbamazepine. Any observed effects on drugs metabolized via CYP3A4 were minimally impacted at doses of 900mg per day or greater. Refer to table 1 for summary.

Side effects:

Cognitive impairment associated with carbamazepine has been directly linked to the concentration of the parent drug as well as the epoxide metabolite.³¹ As oxcarbazepine does not form an epoxide-intermediate, it was expected that it would be better tolerated. Though the true population data is ambiguous, an analysis of head to head trials between patients treated with carbamazepine and oxcarbazepine highlighted oxcarbazepine as overall better tolerated.¹³ Eslicarbazepine was expected to exhibit an even more tolerable profile by reducing the peak of MHD after administration; this has yet to be clinically validated.⁵¹

Carbamazepine has a warning for hematologic side effects, namely aplastic anemia or agranulocytosis.¹¹ It is not fully understood why oxcarbazepine and eslicarbazepine do not share this warning. This is often related to the lack of epoxide intermediate formation. However, a competing hypothesis attributes this to carbamazepine's binding and interaction with peripheral benzodiazepine (p-BZD) receptors, which can be found on lymphocytes.⁶ There is no definitive evidence to outline whether it is the parent drug or epoxide intermediate of carbamazepine that interacts with these receptors, but it is clear that oxcarbazepine and eslicarbazepine do not share this receptor activity. It is also believed that carbamazepine's activity at these p-BZD receptors helps mitigate its propensity to induce syndrome of inappropriate diuretic hormone (SiADH).⁴⁹ Both oxcarbazepine and carbamazepine carry a warning for drug-induced SiADH and hyponatremia; however,

this occurs significantly more often in patients treated with oxcarbazepine as compared to carbamazepine, in a dose-dependent fashion.^{3,32}

Another caution for use of these agents is dermatologic events. It is recommended that patients of Asian descent be tested for HLA-B*1502 and HLA-A*31:01 genes as this has been linked to a 10-fold increased risk of developing Stevens Johnson Syndrome (SJS).¹¹ Although there is a warning for potential dermatologic adverse events with oxcarbazepine and eslicarbazepine, it appears to be better tolerated. It was noted that 75% of patients who experienced serious dermatitis with carbamazepine tolerated oxcarbazepine.³²

With each developmental improvement in these medications, there is a corresponding improvement in side effect profile. Previously, differing metabolic pathways were believed to be responsible for improved tolerability, but isolating the active moiety may be the key. As population data describing the tolerability of eslicarbazepine becomes available, it will add to the current understanding of what most influences the side effect profile of these medications.

<Table 2>

Evidence for pain:

Carbamazepine is approved for the use in trigeminal neuralgia and is currently the drug of choice for this condition.^{33,47} While this is the only true FDA indication for pain, there is some evidence to support benefit when used for tabetic lightning pains, post-sympathectomy neuralgia, diabetic neuropathy, glossopharyngeal neuralgia, and phantom limb pain.^{19,20,33,54,56,58} Oxcarbazepine does not carry an FDA-approved indication for trigeminal neuralgia. However, the American Academy of Neurology (AAN) guidelines for trigeminal neuralgia recommend oxcarbazepine as a reasonable first-line option.³³ Furthermore, available evidence suggests efficacy with oxcarbazepine for trigeminal neuralgia that may align with that of carbamazepine.⁷³

Benefit for allodynia, diabetic neuropathy, paroxysmal symptoms in multiple sclerosis, and peripheral neuropathy has also been recognized.^{7,12,15,40,54,60,68} Case reports are available endorsing its use in post-herpetic neuralgia refractory to gabapentin, regional complex pain syndrome refractory to gabapentin, and radiculopathy refractory to gabapentin.^{13,14}

Beyond current evidence in pain, recent studies have illustrated that patients with a specific pain phenotype may experience maximum benefit from treatment with oxcarbazepine.³⁶ In a study evaluating response to oxcarbazepine, the inter-phenotype categorized as “irritable nociceptor” responded better to oxcarbazepine for total pain as well as deep aching pain, lancinating pain, and pressure evoked pain than the non-irritable nociceptor type. There was also a greater reduction in pain-related sleep disturbances.³⁶ Similarly, a recent study evaluated the effect of carbamazepine on 2 patients with inherited erythromelgia, specifically with S241T mutation in the Nav1.7 sodium channel.³⁰ Carbamazepine was found to reduce warmth-induced hyperactivity in dorsal root ganglia neurons in these patients as expected by previous genomic analysis. Patients also reported reduction in pain scores. These studies are encouraging and should catalyze interest for additional research in the area of genomic-guided pain management.³⁰ Please see table 2 for studied doses and level of evidence.

Esclicarbazepine was approved for use in the United States in 2015; therefore, few studies for pain have been conducted. However, there is data to support its use in multiple sclerosis with refractory trigeminal neuralgia.²⁹

Discussion:

At this time, a primary focus of clinical practice is minimizing and decreasing reliance on opioid therapy which is a significant change for many patients, and one many will not tolerate without effective alternatives to address their pain. There is increased emphasis on finding appropriate adjunct or alternative therapies that are effective but not habit-forming. Current treatment guidelines for neuropathic pain recommend the gabapentinoids (gabapentin & pregabalin) as first line medications with strong evidence for pain, however,

sodium channel inhibitors are currently considered a second-line option for neuropathic pain along with many other medications.²⁷ Many providers have questioned the utility of carbamazepine or oxcarbazepine for pain based on the lack of endorsement from the AAN guidelines for diabetic peripheral neuropathy; however, this should be balanced against a more recent meta-analysis (2015) of neuropathic pain by the International Association for the Study of Pain.²⁷ In that meta-analysis, they suggest oxcarbazepine may have a specialized role due to trial results suggesting that oxcarbazepine might be significantly more effective in subgroups of patients with specific phenotypic expression.^{9,27}

Among the three trials referenced by AAN, reduction in pain scores was observed in patients treated with doses >1200mg/day of oxcarbazepine.⁹ While there is not currently enough evidence to support a dose-dependent effect, trends in available evidence would suggest that benefit with oxcarbazepine for peripheral neuropathy is mostly observed at doses of >900mg/day. Although the disparity between study quantity and quality supporting use for various pain conditions between first and second-line medications is profound, emerging literature continues to highlight the potential uses of sodium channel inhibitors for pain management, which remains underappreciated.²⁷

While there is a lack of literature to guide the use of voltage-gated sodium channels in neuropathic pain in comparison to gabapentinoids, the majority of literature evaluating the use of these agents for pain is in neuropathic pain syndromes. Notably, many Navs have been linked to neuropathic pain transmission.^{55,69} However, some have been linked also to inflammatory pain demonstrating that prostaglandins enhance the activity of Nav1.9 and Nav1.7.^{55,67,69} Because non-steroidal anti-inflammatory (NSAID) agents block the formation of prostaglandins, it is not suggested that voltage-gated sodium channels replace NSAIDs for inflammatory pain. However, the pharmacology suggests that in patients unable to tolerate NSAIDs because of gastrointestinal or cardiovascular complications, a trial of sodium channel inhibitors may be effective. Clinical trials are needed to fully evaluate and characterize the targeted use of voltage-gated sodium channel blockers and place in therapy for inflammatory pain.

An area that has yet to be elucidated and may play a significant role in the development of medications for chronic pain management is targeting specific voltage gated sodium channel subtypes. Investigators are currently attempting to design drugs that selectively inhibit specific Navs; however, this may prove to be difficult given the channel structural similarities. In lieu of pending new drug approvals for specific sodium channel inhibitors, perhaps clinicians should reconsider utilization of carbamazepine and oxcarbazepine.

Carbamazepine use has historically been limited due to undesirable pharmacokinetics and adverse effect profiles and oxcarbazepine use decreased by association and assumption of similar effects. Research has validated oxcarbazepine's improved pharmacokinetic and adverse effect profile compared to carbamazepine but interest in additional research into pain conditions has not been emphasized. The arrival of eslicarbazepine has generated new and promising evidence for sodium channel blockers as a class. Identification of sodium channel subtypes and their connection to pain etiologies justifies additional research for application into clinical practice.

Conclusion:

The global effort to minimize and decrease reliance on opioid therapy is complicated by availability of effective treatment alternatives. There is significant disparity in the evidence gap between 1st and 2nd line neuropathic pain medications that needs to be addressed through further research into specific pain conditions. In addition, targeting musculoskeletal and neuroinflammatory disorders with sodium channel inhibitors may be a new frontier in pain research. Identification of sodium channel subtypes with links to specific pain conditions and the ability to target them hints at the potential for truly individualized therapy and the necessary transformation of pain care. Sodium channel inhibitors are underutilized based on available evidence, and emerging research has identified this area as promising for additional clinical trials to better guide clinical practice.

Accepted Manuscript

References:

1. Almeida L, Soares-da-Silva P. Eslicarbazepine Acetate (BIA 2-093). *Neurotherapeutics: The Journal of the American Society for Experimental Neuro Therapeutics* 4: 88-96,2007.
2. Ambrosio A, Soars-da-Silva P, Carvalho C, Carvalho A. Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024*. *Neurochemical Research* 27:121-30, 2002.
3. Amelvoort T Bakshi R, Devaux C, Schwabe S. Hyponatremia Associated with Carbamazepine and Oxcarbazepine Therapy: a review. *Epilepsia* 35(1):1528-1557, 1994.
4. Andreasen A, Brosen K, Damkier P. A comparative pharmacokinetic study in healthy volunteers of the effect of carbamazepine and oxcarbazepine on cyp3a4. *Epilepsia* 48(3):490-496, 2007.
5. Baker, M.D., Chandra, S. Y., Ding, Y., Waxman, S. G., Wood, J. N. GTP-induced tetrodotoxin-resistant Na⁺ current regulates excitability in mouse and rat small diameter sensory neurones. *J. Physiol* 548(2): 373-383, 2003
6. Bertilsson L, Tomsin T. Clinical Pharmacokinetics of Carbamazepine. *Clin Pharmacokinet* 3:128-143, 1978.
7. Beydoun A, Schmidt D, D'Souza J. Meta-analysis of comparative trials of oxcarbazepine versus carbamazepine in trigeminal neuralgia. *J Pain* 3(Suppl 1):38, 2002.
8. Bialer M, Soares-da-Silva. Pharmacokinetics and drug interactions of eslicarbazepine acetate. *Epilepsia* 53(6):935-946, 2012.
9. Bril V, England J, Franklin G, Backonja M, Cohen J, Del Toro D, Feldman E, Iverson D, Perkins B, Russell JW, Zochodne D. Evidence-based guideline: Treatment of painful diabetic neuropathy. *Neurology* 76:1-8, 2011.
10. Cao L, McDonnell A, Nitzsche A, Alexandrou A, Saintot PP, Loucif A, Brown A, Young G, Mis M, Randall A, Waxman S, Stanley P, Kirby S, Tarabar S, Gutteridge A, Butt R, McKernan R, Whiting P, Ali Z, Bilslund J, Stevens E. Pharmacological reversal of pain phenotype in iPSC-derived sensory neurons and human subjects with inherited erythromelalgia, *Science Translational Medicine* 8(335): 335-56, 2016.

11. Carbamazepine [package insert]. East Hanover, New Jersey: Novartis; September 2015.
12. Carrazana E, Beydoun A, Kobetz S, Constantine S. An open label, prospective trial of oxcarbazepine in the treatment of painful diabetic neuropathy. *J Pain* 3(Suppl. 1):38, 2002.
13. Carranza E, Mikoshiba I. Rational and Evidence for the Use of Oxcarbazepine in Neuropathic Pain. *Journal of pain and Symptom management* 25(5):s31-s35, 2003.
14. Criscuolo S, Auletta C, Lippi S, Brogi F, Brogi A. Oxcarbazepine monotherapy in postherpetic neuralgia unresponsive to carbamazepine and gabapentin. *Act Neurol Scand* 111(4):229-232,2005.
15. Cummins T, Dib-Hajj S, Waxman S. Electrophysiological properties of mutant Nav1.7 sodium channels in a painful inherited neuropathy. *The Journal of Neuroscience* 24(38):8232-8236, 2004.
16. Dib-Hajj S, Black J, Waxman S. NaV1.9: A sodium channel linked to human pain. *Nat Rev Neurosci*, 16: 511-19, 2015.
17. Dib-Hajj S, Black, J, Waxman S. Voltage-gated sodium channels: therapeutic targets for pain. *Pain Med* 10 (7): 1260-1269, 2009.
18. Dib-Hajj S, Yang Y, Black J, Waxman S. The NaV1.7 sodium channel: from molecule to man. *Nature Rev Neurosci* 14(1): 49-62, 2013.
19. Ekbom KA. Carbamazepine in the Treatment of Tabetic Lightning Pains. *Arch Neurol* 26:374-378, 1972.
20. Ekbom KA, Westerberg CE. Carbamazepine in Glossopharyngeal Neuralgia. *Arch Neurol* 14:595-596, 1966.
21. Faber C, Hoeijmakers J, Ahn H, Cheng X, Han C, Choi J, Estacion M, Lauria G, Vanhoutte E, Gerrits M, Dib-Hajj S, Drenth J, Waxman S, and Merkies I. Gain-of-function NaV1.7 mutations in idiopathic small fiber neuropathy. *Ann Neurol* 71(1):26-39, 2012.
22. Faber C, Lauria G, Merkies I, Cheng X, Han C, Ahn H, Persson, A, Hoeijmakers J, Gerrits M, Pierro T, Lombardi R, Kapetis D, Dib-Hajj S, Waxman S. Gain-of-function NaV1.8 mutations in painful neuropathy. *PNAS* 109:19444-19449, 2012.

23. Faigle J, Menge G. Metabolic characteristics of oxcarbazepine and their beneficial implications for enzyme induction and drug interactions. *Behav Neurol* 3(1):21-30, 1990.
24. Falcao A, Pinto R, Nunes T, Soares-da-Silva P. Effect of repeated administration of eslicarbazepine acetate on pharmacokinetics of simvastatin in healthy subjects. *Epilepsy Research* 106:244-249, 2013.
25. Farago F. Trigeminal neuralgia: its treatment with two new carbamazepine analogues. *European neurology* 26(2):73-83, 1987.
26. Fink R. Pain assessment: the cornerstone to optimal pain management. *Proceedings (Baylor University Medical Center)*13:236-239, 2000.
27. Finnerup N, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, Gilron I, Haanpaa M, Hansson P, Jensen TS, Kamerman PR, Lund K, Moore A, Raja SN, Rice AS, Rowbotham M, Sena E, Siddal P, Smith BH, Wallace M. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. *Lancet Neurol* 14(2):162-73, 2015.
28. Flesch G. Overview of the clinical pharmacokinetics of oxcarbazepine. *Clin Drug Invest* 24(4):185-203, 2004.
29. Gaber T, Kyu MM, Oo W Eslicarbazepine use in multiple sclerosis with refractory trigeminal neuralgia. *BJMP* 6(1):602, 2013
30. Geha P, Yang Y, Estacion M, Schulman B, Tokuno H, Apkarian AV, Dib-Hajj S, Waxman S. Pharmacotherapy for Pain in a Family with Inherited Erythromelalgia Guided by Genomic Analysis and Functional Profiling. *JAMA Neurol* 73(6):659-667, 2016.
31. Gillham RA, Williams N, Weidmann K, Butler E, Larkin JG, Brodie MJ. Concentration-effect relationships with carbamazepine and its epoxide on psychomotor and cognitive function in epileptic patients. *Journal of Neurology, Neurosurgery and Psychiatry* 51:929-933, 1988.
32. Grant S, Faulds D. Oxcarbazepine: A review of its Pharmacology and Therapeutic Potential in Epilepsy, Trigeminal Neuralgia and Affective Disorders. *Drugs* 43(6):873-888, 1992.

33. Gronseth G, Cruccu G, Alksne J, Argoff C, Brainin M, Burchiel K, Nurmikko T, and Zakrewska M. Practice Parameter: The diagnostic evaluation and treatment of trigeminal neuralgia. *Neurology* 15(71):1183-1190, 2008.
34. Hains B, Saab C, Klein J, Craner M, Waxman S. Altered Sodium Channel Expression in Second-Order Spinal Sensory Neurons Contributes to Pain after Peripheral Nerve Injury. *Journal of Neuroscience* 24(20):4832-4839, 2004.
35. Han C, Huang J, Waxman S. Sodium Channel NaV1.8: Emerging links to human disease. *Neurology* 86:473-483, 2016.
36. Holbech J, Bach FW, Finnerup NB, Jensen TS, Sindrup SH. Pain phenotype as a predictor for drug response in painful polyneuropathy-a retrospective analysis of data from controlled clinical trials. *PAIN* 157(6):1305-1313, 2016.
37. Huang J, Han C, Estacion M, Vasylyev D, Hoeijmakers JG, Gerrits MM, Tyrrell L, Lauria G, Faber CG, Dib-Hajj SD, Merkies IS, Waxman SG; PROPANE study group. Gain-of-function mutations in sodium channel Nav1.9 in painful neuropathy. *Brain: A Journal of Neurology* 137:1627-42, 2014
38. Institute of Medicine. *Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research*. NIH National Academy of Sciences, June 29, 2011. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22553896>. Accessed December 13, 2016.
39. Jarvis M, Honore P, Shieh C, Chapman M, Joshi D, Zhang XF, Kort N, Carroll W, Marron B, Atkinson R, Thomas J, Liu D, Krambis M, Liu Y, McGaraughty D, Chu K, Roeloffs R, Zhong C, Mikusa JP, Hernandez G, Gauvin D, Wade C, Zhu C, Pai M, Scanio M, Shi L, Drizin I, Gregg R, Matulenko M, Hakeem A, Gross M, Johnson M, Marsh K, Wagoner PK, Sullivan JP, Faltynek CR, Krafte DS. A-803467, a potent and selective Na_v1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. *Proc Natl Acad Sci U S A* 104(20): 8520–8525, 2007.
40. Jenkins K, Kaplan SE, Leahy LF, Sang CN. Oxcarbazepine in central neuropathic pain with allodynia following spinal cord injury. *J Pain* 3(10),2002.

41. Johannessen LC, Svendsen T, Dinarevic J, Kufaaas R, Reimers A, Brodtkorb E, Baftiu A, Margrete B, Johannessen S. The Impact of Pharmacokinetic Interactions with Eslicarazepine acetate versus Oxcarbazepine and Carbamazepine in Clinical practice. *Therapeutic Drug Monitoring* 38(4): 499-505, 2016.
42. Killian JM, Fromm GH. Carbamazepine in the treatment of neuralgia use and side effects. *Arch Neurol* 19(2):129-136, 1968.
43. Kramer G, Tettenborn B, Klosterskov Jensen P, Menge GP, Stoll KD. Oxcarbazepine does not affect the anticoagulant activity of warfarin. *Epilepsia* 33(6):1145-1148, 1992.
44. Larkin JG, McKee PJ, Forrest G, Beastall GH, Park BK, Lowrie JI, Lloyd P, Brodie MJ. Lack of enzyme induction with oxcarbazepine (600mg daily) in healthy subjects. *Br J Clin Pharmac* 31:65-71, 1991.
45. Lebovits AH, Florence I, Bathina R, Hunko V, Fox MT, Branble CY. Pain Knowledge and Attitudes of Healthcare Providers: Practice Characteristics Differences. *The Clinical Journal of Pain* 13: 237-243, 1997.
46. Librach S L. Managing chronic pain in family practice. *Can Fam Physician* 39:539-544, 1993.
47. Lindström P. The analgesic effect of carbamazepine in trigeminal neuralgia. *PAIN* 30:S85, 1987.
48. Liu M, Wood J. The Roles of Sodium Channels in Nociception: implications for mechanisms of neuropathic pain. *Pain Medicine* 12:93-99, 2011.
49. Marangos P, Post R, Patel J, Zander K, Parma A, Weiss S. Specific and Potent interactions of Carbamazepine with Brain Adenosine Receptors. *European Journal of Pharmacology* 93(3-4): 175-182, 1983.
50. McKee P, Blacklaw J, Forrest G, Gillham R, Walker S, Connelly D, Brodie M. A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients. *Br J clin Pharmac* 37(1):27-32, 1994.

51. New Drug Approvals Tag Archives: eslicarbazepine acetate.
<https://newdrugapprovals.org/tag/eslicarbaepine-acetate/>. Accessed 9/28/16.
52. Oxcarbazepine [package insert]. East Hanover, New Jersey: Novartis; July 2014.
53. Patsalos Pn, Zakrzewska JM, Elyas AA. Dose dependent enzyme induction by oxcarbazepine? *Eur J Clin Pharmacol* 39(2):187-188, 1990.
54. Patterson J. Carbamazepine in the treatment of phantom limb pain. *South Med J* 81(9):1100-2, 1988.
55. Priest BT, Murphy BA, Lindia JA, Diaz C, Abbadie C, Ritter A, Liberator P, Lyers LM, Kash SF, Kohler MG, Kaczorowski GJ, MacIntyre DE, Mart WJ. Contribution of the tetrodotoxin-resistant voltage-gated sodium channel Nav1.9 to sensory transmission and nociceptive behavior. *PNAS* 102: 9382-9387, 2005.
56. Raskin N, Levinson S, Hoffman P, Pickett J, Fields H. Postsympathectomy Neuralgia: Amelioration with diphenylhydantoin and carbamazepine. *The American Journal of Surgery* 128(1):75-8, 1974.
57. Royal MA, Jenson M, Bhakta B, Gunyea I, Movva V, Ward S. An open-label trial of oxcarbazepine in patients with complex regional pain syndrome refractory to gabapentin. *J Pain* 3(2):41,2002.
58. Rull JA, Quibrera R, Gonzalez-Millan H, Castaneda OL. Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine (Tegretol®): double blind crossover trial. *Diabetologia* 5(4):215-8, 1969.
59. Schmidt D, Elger C. What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs? *Epilepsy Behav* 5(5): 627-635, 2004.
60. Solaro C, Restivo D, Mancardi GL, Tanganelli P. Oxcarbazepine for treating paroxysmal painful symptoms in multiple sclerosis: a pilot study. *Neuro Sci* 28(3):156-158, 2007.
61. Spina E, Pisani F, Perucca E. Clinically Significant Pharmacokinetic Drug Interactions with Carbamazepine: an update. *Clin Pharmacokinet* 31(3):198-214, 1996.

62. Szabo L. Doctors told to avoid prescribing opiates for chronic pain. USA Today. March 16, 2016. <http://www.usatoday.com/story/news/2016/03/15/cdc-issues-new-guidelines-opiate-prescribing-reduce-abuse-overdoses/81809704/>. Accessed 11/30/16.
63. Tarnawa I, Bolcskei, Hedvig, Kocsis, Pal. Blockers of Voltage-Gated Sodium Channels for the Treatment of Central Nervous System Diseases. *Recent Patents on CNS Drug Discovery* 2(1):57-58, 2007.
64. Tecoma E. Oxcarbazepine. *Epilepsia* 40:37-46, 1999.
65. Tomic M, Vuckovic SM, Stepanovic-Petrovic RM, Ugresic N, Prostran MS, Boskovic B. The anti-hyperalgesic effects of carbamazepine and oxcarbazepine are attenuated by the treatment with adenosine receptor antagonists. *PAIN* 111(3):253-260, 2004.
66. Vaz-da-Silva M, Almeida L, Falcao A, Soares E, Maia J, Nunes T, Soares-da-Silva P. Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period. *Clinical Therapeutics* 32(1):179-192, 2010.
67. Wada A. Role of Voltage-Dependent Sodium Channels in Neuronal Development, Pain, and Neurodegeneration. *J Pharmacol Sci.* 102(3):253-268, 2006.
68. Ward S, Royal M, Jenson M, Bhakta B, Gunyea I, Movva V. An open-label trial of oxcarbazepine in patients with radiculopathy refractory to gabapentin. *J Pain* 3(2):42, 2002.
69. Wood JN, Boorman JP, Okuse K, Baker MD. Voltage-Gated Sodium Channels and Pain Pathways. *Journal of Neurobiology* 61(1): 55-71, 2004.
70. Zacarra G, Gangemi P, Bendoni L, Menge G, Schwabe S, Monza G. Influence of single and repeated doses of oxcarbazepine on the pharmacokinetic profile of felodipine. *Therapeutic Drug Monitoring* 15:39-42, 1993.
71. Zacarra G, Giovannelli F, Cincotta M, Carelli A, Verrotti A. Clinical Utility of Eslicarbazepine: current evidence. *Drug Des Devel Ther* 9:781-9, 2015.

72. Zakrzewska JM, Palmer J, Morisset V, Giblin GM, Obermann M, Ettlin DA, Cruccu G, Bendtsen L, Estacion M, Derjean D, Waxman SG, Layton G, Gunn K, Tate S; study investigators. Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomized withdrawal phase 2a trial. *Lancet Neurol* (4):291-300, 2017.
73. Zakrzewska JM, Patsalos PN. Oxcarbazepine: a new drug in the management of intractable trigeminal neuralgia. *J Neurol neurosurg Psychiatry* 52:472-476, 1989.

Accepted Manuscript





Figure 1: Sodium Channel Subtypes and Associated Pain Syndromes

Table 1. Pharmacokinetic and Pharmacodynamic comparison of prescription sodium channel blockers

	Carbamazepine ^{2,6,61} Tegretol®		Oxcarbazepine ^{1,13,28,41,59,64} Trileptal®		Eslicarbazepine ^{1,2,8} Aptiom®	
						
Receptor Activity	alpha subunit of voltage-gated Na Channels	K_I resting: 984 μm K_I inactivated: 47.8 μm	Site 2 of alpha subunit of voltage-gated Na Channels	K_I : higher affinity for inactive state	Site 2 of alpha subunit of voltage-gated Na channels	K_I resting: 3315 μm K_I inactivated: 99.9 μm
Bioavailability	70% ↑ with food		No effect with/without food		No effect with/without food	
Protein Binding	70-80%		40%		30%	
Metabolism	Hepatic: Phase I CYP3A4 (major) CYP2C8 (minor)		Step 1: metabolism of oxcarbazepine by arylketone reductase to MHD Step 2: MHD metabolism: Hepatic: Phase I (CYP450-minor) ~4% to inactive metabolite Hepatic: Phase II: glucuronidation		Hepatic: Phase II Esterases, glucuronidation	
CYP450 interaction	Parent drug induces CYPs 3A, 2B, 2C, 2E and glucuronyl transferases		Weak inducer of CYP3A4 at doses $\geq 900\text{mg/day}$ OXB MHD inhibits CYP2C9 at $k_I > 1350\text{mol/L}$ (minor) MHD inhibits CYP 2C19 at $k_I: 88\text{mol/L}$ (minor)		Weak inducer of CYP3A4 at doses $\geq 800\text{mg/day}$ Minor inhibition of CYP2C19	
Differences in Side effects	<input type="checkbox"/> Hematologic <input type="checkbox"/> Dermatologic adverse effects		<input type="checkbox"/> Hyponatremia		Unknown at present	

BZD = benzodiazepine

 K_I = binding affinity; lower numbers indicating stronger binding affinity

MHD= mono-hydroxy active metabolite of oxcarbazepine

Cyp450= cytochrome p450 enzyme system

Accepted Manuscript

Table 2: Evidence for pain efficacy in commonly prescribed sodium channel blockers

Pain Syndrome	Carbamazepine	Oxcarbazepine	Esclicarbazepine	Level of Evidence*
Tabetic Lightning Pains	800mg/day ¹⁹			Low
Trigeminal Neuralgia	200-1200mg/day ³³			High
		1200-2400mg/day ^{15, 7, 25, 47, 73}		Moderate
			(Multiple sclerosis with refractory trigeminal neuralgia) 400mg/day ²⁹	Low
Post-sympathectomy Neuralgia	600mg/day ⁵⁶			Low
Diabetic Neuropathy	200-600mg/day (often requires >600mg/day) ⁵⁸			Moderate
		150-1200mg/day (often requires >600mg/day; average dose ~800mg/day) ¹²		Low
Glossopharyngeal neuralgia	400-800mg/day ²⁰			Low
Phantom Limb Pain	800mg/day ⁵⁴			Low
Spinal Cord Injury w/ Allodynia		900mg/day ⁴⁰		Low
Postherpetic Neuralgia		(refractory to CBZ and gabapentin) 900mg/day ¹⁶		Low
Paroxysmal Pain Symptoms		1000mg/day ⁶⁰		Low
Complex Regional Pain Syndrome		(refractory to gabapentin) 150-2000mg/day ⁵⁷		Low

Radiculopathy		(Refractory to gabapentin) 150-900mg/day ⁶⁸		Low
---------------	--	---	--	-----

CBZ=carbamazepine; *GRADE Classification for Level of Evidence

Accepted Manuscript